Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELDNNASDAQ:ORGSNASDAQ:VTGNNASDAQ:YMTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELDNEledon Pharmaceuticals$2.87-0.7%$3.24$2.00▼$5.54$171.86M0.08275,767 shs191,522 shsORGSOrgenesis$1.95-6.3%$2.58$0.87▼$10.80$9.36M0.7210,273 shs3,083 shsVTGNVistagen Therapeutics$2.32+3.6%$2.39$1.90▼$4.75$64.65M0.67167,372 shs47,599 shsYMTXYumanity Therapeutics$0.68$0.95▼$3.78$7.46M0.32473,083 shs6,790 shs10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELDNEledon Pharmaceuticals-0.69%-7.42%-2.38%-33.72%+24.24%ORGSOrgenesis-6.25%-17.20%-1.02%+18.36%+194,999,900.00%VTGNVistagen Therapeutics+3.57%-1.28%+9.43%-14.07%-46.91%YMTXYumanity Therapeutics0.00%0.00%0.00%0.00%+23.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationELDNEledon Pharmaceuticals2.1903 of 5 stars3.52.00.00.03.61.70.0ORGSOrgenesisN/AN/AN/AN/AN/AN/AN/AN/AVTGNVistagen Therapeutics1.8707 of 5 stars0.04.00.00.03.41.71.3YMTXYumanity TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELDNEledon Pharmaceuticals 3.00Buy$12.50335.54% UpsideORGSOrgenesis 0.00N/AN/AN/AVTGNVistagen Therapeutics 4.00Strong BuyN/AN/AYMTXYumanity Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELDNEledon PharmaceuticalsN/AN/AN/AN/A$0.30 per shareN/AORGSOrgenesis$662K14.14N/AN/A($6.58) per share-0.30VTGNVistagen Therapeutics$698K95.93N/AN/A$2.81 per share0.83YMTXYumanity Therapeutics$4.84M0.00N/AN/A$2.28 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELDNEledon Pharmaceuticals-$116.54M-$2.36N/AN/AN/AN/A-189.99%-28.17%N/AORGSOrgenesis-$55.36MN/A0.00∞N/A-3,827.81%N/A-130.18%5/19/2025 (Estimated)VTGNVistagen Therapeutics-$29.36M-$1.48N/AN/AN/A-6,777.08%-48.12%-43.80%6/10/2025 (Estimated)YMTXYumanity Therapeutics-$39.50M-$3.00N/AN/AN/A-660.61%-263.34%-107.08%N/ALatest ORGS, VTGN, ELDN, and YMTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/10/2025Q4 2025VTGNVistagen Therapeutics-$0.53N/AN/AN/A$0.18 millionN/A3/20/2025Q4 2024ELDNEledon Pharmaceuticals-$0.32-$0.64-$0.32-$0.64N/AN/A2/13/2025Q3 2025VTGNVistagen Therapeutics-$0.48-$0.46+$0.02-$0.46$0.18 million$230.00 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthELDNEledon PharmaceuticalsN/AN/AN/AN/AN/AORGSOrgenesisN/AN/AN/AN/AN/AVTGNVistagen TherapeuticsN/AN/AN/AN/AN/AYMTXYumanity TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELDNEledon PharmaceuticalsN/A6.536.53ORGSOrgenesisN/A0.070.07VTGNVistagen TherapeuticsN/A9.359.35YMTXYumanity TherapeuticsN/A2.212.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELDNEledon Pharmaceuticals56.77%ORGSOrgenesis22.56%VTGNVistagen Therapeutics78.39%YMTXYumanity Therapeutics25.10%Insider OwnershipCompanyInsider OwnershipELDNEledon Pharmaceuticals11.70%ORGSOrgenesis5.66%VTGNVistagen Therapeutics1.29%YMTXYumanity Therapeutics12.45%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELDNEledon Pharmaceuticals1059.88 million52.75 millionOptionableORGSOrgenesis1504.80 million4.53 millionOptionableVTGNVistagen Therapeutics4028.86 million28.49 millionOptionableYMTXYumanity Therapeutics4010.86 million9.50 millionNot OptionableORGS, VTGN, ELDN, and YMTX HeadlinesRecent News About These CompaniesBoard of GovernorsJuly 20, 2024 | bc.eduJSPR Jasper Therapeutics, Inc.March 20, 2024 | seekingalpha.comCara Therapeutics Inc CARANovember 3, 2023 | morningstar.comYumanity Therapeutics Inc.October 6, 2023 | thestreet.comFormer Onyx CEO Returns to Biotech to Launch Boston Start UpJuly 5, 2023 | thestreet.comKineta raises $6M through registered direct offeringMay 1, 2023 | bizjournals.comColorectal Cancer Therapeutics Market Size to Surpass US$ 24.58 Billion by 2030 - Growth Plus ReportsFebruary 22, 2023 | finance.yahoo.comYumanity Therapeutics's Return On Capital Employed InsightsDecember 26, 2022 | msn.comKineta finalizes reverse merger with Yumanity, secures additional fundingDecember 20, 2022 | bizjournals.comYumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to ...December 5, 2022 | bakersfield.comYumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with KinetaDecember 5, 2022 | finance.yahoo.comWhy Is Yumanity Therapeutics (YMTX) Stock Up Today?December 5, 2022 | investorplace.comYumanity Therapeutics Inc: Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate DevelopmentsNovember 14, 2022 | finanznachrichten.deYumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate DevelopmentsNovember 14, 2022 | finance.yahoo.comYumanity Therapeutics Announces Effectiveness of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta, Inc.November 10, 2022 | finance.yahoo.comYumanity Therapeutics Announces Filing of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with KinetaAugust 29, 2022 | finance.yahoo.comYumanity Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate DevelopmentsAugust 4, 2022 | finance.yahoo.comGlioblastoma Pipeline Analysis: Key Pharma Players Set to Develop Novel Therapies and Explore Countless OpportunitiesJuly 14, 2022 | medgadget.comYUMANITY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of…July 5, 2022 | lawyer-monthly.comInside Kineta's plans after unveiling reverse merger dealJune 8, 2022 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeORGS, VTGN, ELDN, and YMTX Company DescriptionsEledon Pharmaceuticals NASDAQ:ELDN$2.87 -0.02 (-0.69%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$2.88 +0.00 (+0.17%) As of 05/12/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.Orgenesis NASDAQ:ORGS$1.95 -0.13 (-6.25%) As of 05/12/2025 03:39 PM EasternOrgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.Vistagen Therapeutics NASDAQ:VTGN$2.32 +0.08 (+3.57%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$2.32 0.00 (0.00%) As of 05/12/2025 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.Yumanity Therapeutics NASDAQ:YMTXYumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
